X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (46249) 46249
Newspaper Article (13605) 13605
Newsletter (4415) 4415
Magazine Article (474) 474
Trade Publication Article (248) 248
Book Chapter (162) 162
Transcript (148) 148
Web Resource (139) 139
Dissertation (64) 64
Conference Proceeding (27) 27
Book / eBook (22) 22
Streaming Video (14) 14
Book Review (9) 9
Publication (7) 7
Reference (2) 2
Journal / eJournal (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
melanoma (45749) 45749
humans (29984) 29984
cancer (20986) 20986
oncology (20745) 20745
animals (13907) 13907
female (12811) 12811
immunotherapy (12662) 12662
metastasis (12549) 12549
melanoma - drug therapy (11688) 11688
male (10948) 10948
tumors (10369) 10369
mice (10005) 10005
care and treatment (9294) 9294
cancer therapies (8940) 8940
research (8706) 8706
skin cancer (7599) 7599
middle aged (7565) 7565
cell line, tumor (7431) 7431
melanoma - pathology (7247) 7247
apoptosis (7045) 7045
chemotherapy (6561) 6561
drug therapy (6560) 6560
aged (6247) 6247
adult (5963) 5963
clinical trials (5623) 5623
medical research (5159) 5159
patients (4977) 4977
skin neoplasms - drug therapy (4877) 4877
dermatology (4776) 4776
antineoplastic agents - therapeutic use (4554) 4554
metastatic melanoma (4532) 4532
expression (4427) 4427
mutation (4377) 4377
proteins (4313) 4313
immunology (4307) 4307
health aspects (4105) 4105
analysis (3924) 3924
skin neoplasms - pathology (3887) 3887
therapy (3794) 3794
pharmaceutical industry (3608) 3608
cell biology (3585) 3585
antineoplastic agents - pharmacology (3505) 3505
medicine, research & experimental (3374) 3374
treatment outcome (3360) 3360
pharmacology & pharmacy (3347) 3347
lung cancer (3333) 3333
mice, inbred c57bl (3295) 3295
gene expression (3267) 3267
lymphocytes (3263) 3263
kinases (3215) 3215
breast cancer (3180) 3180
malignant-melanoma (3165) 3165
melanoma - metabolism (3133) 3133
melanoma - genetics (3099) 3099
immune system (3076) 3076
melanoma - therapy (3066) 3066
studies (3016) 3016
medicine (2952) 2952
ipilimumab (2910) 2910
survival (2874) 2874
antineoplastic agents (2860) 2860
metastases (2814) 2814
cytotoxicity (2801) 2801
prognosis (2787) 2787
biochemistry & molecular biology (2752) 2752
genetic aspects (2722) 2722
antigens (2712) 2712
antimitotic agents (2611) 2611
medical prognosis (2577) 2577
drugs (2570) 2570
cells (2563) 2563
surgery (2563) 2563
apoptosis - drug effects (2491) 2491
melanoma - secondary (2403) 2403
neoplasm metastasis (2347) 2347
neoplasms - drug therapy (2308) 2308
melanoma, experimental - drug therapy (2305) 2305
development and progression (2289) 2289
cell proliferation - drug effects (2284) 2284
fda approval (2276) 2276
aged, 80 and over (2249) 2249
melanoma - immunology (2233) 2233
research article (2172) 2172
activation (2160) 2160
tumor cells, cultured (2114) 2114
antineoplastic combined chemotherapy protocols - therapeutic use (2098) 2098
signal transduction (2082) 2082
growth (2067) 2067
multidisciplinary sciences (2064) 2064
dendritic cells (2062) 2062
t cells (2054) 2054
angiogenesis (1986) 1986
medicine & public health (1979) 1979
inhibition (1952) 1952
oncology, experimental (1914) 1914
skin (1871) 1871
dose-response relationship, drug (1862) 1862
in-vitro (1843) 1843
cytokines (1840) 1840
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (7) 7
Gerstein Science - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (64196) 64196
German (504) 504
French (305) 305
Japanese (256) 256
Russian (222) 222
Chinese (79) 79
Spanish (71) 71
Polish (51) 51
Italian (48) 48
Czech (28) 28
Portuguese (21) 21
Hungarian (20) 20
Dutch (19) 19
Swedish (16) 16
Danish (10) 10
Korean (9) 9
Turkish (8) 8
Norwegian (6) 6
Finnish (5) 5
Hebrew (5) 5
Croatian (4) 4
Ukrainian (3) 3
Bulgarian (2) 2
Romanian (2) 2
Serbian (2) 2
Slovak (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Nature (London), ISSN 1476-4687, 2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | ErbB Receptors - antagonists & inhibitors | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies
Journal Article
Nature (London), ISSN 1476-4687, 2016, Volume 539, Issue 7629, pp. 443 - 447
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | CTLA-4 | LIGAND | BLOCKADE | CLINICAL ACTIVITY | PHASE-I | PD-1 | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Female | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Lungs | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 11, pp. 1904 - 1911
.... To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical... 
pembrolizumab | autoimmune | nivolumab | elderly | ipilimumab | pediatrics | pregnancy | transplant | organ dysfunction | ALLOGRAFT-REJECTION | PERFORMANCE STATUS | PD-1 BLOCKADE | OPEN-LABEL | CELL LUNG-CANCER | IPILIMUMAB THERAPY | ONCOLOGY | ADVANCED MELANOMA | BRAIN METASTASES | AUTOIMMUNE-DISEASE | T-CELLS | Lung Neoplasms - drug therapy | Melanoma - complications | Age Factors | Humans | Immunosuppressive Agents - therapeutic use | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Hepatitis C, Chronic - complications | Transplant Recipients | Neoplasms - complications | Brain Neoplasms - secondary | Squamous Cell Carcinoma of Head and Neck | Pregnancy Complications, Neoplastic - drug therapy | Female | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - complications | Graft Rejection - prevention & control | Autoimmune Diseases - complications | Head and Neck Neoplasms - drug therapy | Brain Neoplasms - drug therapy | Lung Neoplasms - complications | Neoplasms - drug therapy | Pregnancy | Carcinoma, Non-Small-Cell Lung - complications | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Hepatitis B, Chronic - complications | Carcinoma, Squamous Cell - complications | Melanoma - drug therapy | Nivolumab | HIV Infections - complications | Head and Neck Neoplasms - complications | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Renal Cell - complications | Immunocompromised Host | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Virus diseases | Care and treatment | Dosage and administration | Research | Cell death | Immunosuppressive agents | Medical research | Brain | Populations | Toxicity | Decision making | Mortality | Disorders | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Patients | Regulatory approval | Metastases | Inhibitors | Immune checkpoint | Aggregates | Lymphocytes | Safety | Autoimmune diseases | Cancer | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2443 - 2454
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | THERAPY | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | MEMBER | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article